



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

RECEIVED 07 September 2023
ACCEPTED 07 September 2023
PUBLISHED 20 September 2023

CITATION
Frontiers Production Office (2023)
Erratum: Characterization and outcome
of post-transplant lymphoproliferative
disorders within a collaborative study.
Front. Oncol. 13:1290218.
doi: 10.3389/fonc.2023.1290218

COPYRIGHT
© 2023 Frontiers Production Office. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Erratum: Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

PTLD, Epstein - Barr virus, allogeneic hematopoietic stem cell transplantation, solid organ transplantation, outcome

An Erratum on

Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study

by Lückemeier P, Radujkovic A, Holtick U, Kurch L, Monecke A, Platzbecker U, Herling M and Kayser S (2023) *Front. Oncol.* 13:1208028. doi: 10.3389/fonc.2023.1208028

Due to a production error, there was a mistake in the footnote for [Table 1](#) as published. The abbreviations were written as ^aSince/at diagnosis of PTL, respectively. ^bWhere applicable (i.e., CD20+, EBV-associated, IS still ongoing).

7 + 3, cytarabine and daunorubicin; (s)AML, (secondary) acute myeloid leukemia; Assoc, associated; sAA, severe aplastic anemia; AVD, adriamycin, vinblastine, dacarbazine; Benda, Bendamustine; BV, brentuximab-vedotin; CAD, cyclophosphamide, doxorubicin, and dexamethasone; cALL, common acute lymphoblastic leukemia; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; cHL, classic Hodgkin lymphoma; CKD, chronic kidney disease; CNL, Chronic neutrophilic leukemia; DLBCL, diffuse large B-cell lymphoma; DLI, Donor lymphocyte infusion; GMALL07/2003, study protocol containing daunorubicin and doxorubicin; GMALL-B-NHL 2002, protocol containing R, Dexamethasone, vincristine, MTX, ifosfamide, cytarabine, etoposide, cyclophosphamide, doxorubicin; HCC, Hepatocellular carcinoma; IDA-FLAG, idarubicin, fludarabine, cytarabine, G-CSF; IS, immunosuppression; Mito-FLAG, mitoxantrone, fludarabine, cytarabine, G-CSF; Monom, monomorphic; MTX, Methotrexate; PBL, plasmablastic lymphoma; PCL, plasma cell leukemia; PD, Progressive disease; Pola, Polatuzumab-Vedotin; PSC, Primary sclerosing cholangitis; R, Rituximab; RIS, Reduction of immunosuppression; RTx, Radiotherapy; T-LBL, T-lymphoblastic lymphoma; T1D, Type 1 diabetes; TAD, thalidomide, doxorubicin, Dexamethasone; T-ALL, T-acute lymphoblastic leukemia; VST, Virus-specific T cells. Values in bold means the summarized values.⁷

The correct footnote appears below. The publisher apologizes for this mistake.

^aSince/at diagnosis of PTL, respectively. ^bWhere applicable (i.e., CD20+, EBV-associated, IS still ongoing).

Abbreviations: 7 + 3=cytarabine and daunorubicin. (s)AML=(secondary) acute myeloid leukemia. assoc.=associated. sAA=severe aplastic anemia. CAD=cyclophosphamide, doxorubicin, and dexamethasone. cALL=common acute lymphoblastic leukemia. cHL=classic Hodgkin lymphoma. CKD=chronic kidney disease. CNL=Chronic neutrophilic leukemia. DLBCL=diffuse large B-cell lymphoma. GMALL07/2003=study protocol containing daunorubicin and doxorubicin. HCC=Hepatocellular carcinoma. IDA-FLAG=idarubicin, fludarabine, cytarabine, G-CSF. Mito-FLAG=mitoxantrone, fludarabine, cytarabine, G-CSF. monom.=monomorphic. PBL=Plasmablastic lymphoma. PCL=plasma cell leukemia. PD=Progressive disease. Pola=Polatuzumab-Vedotin. PSC=Primary sclerosing cholangitis. T-LBL=T-lymphoblastic lymphoma. T1D=Type 1 diabetes. TAD=thalidomide, doxorubicin, Dexa. T-ALL=T-acute lymphoblastic leukemia.

The original version of this article has been updated.

Additionally, due to a production error, there was a mistake in the footnote for Table 2 as published. The abbreviations were written as ‘^aSince/at diagnosis of PTLN, respectively. ^bWhere applicable (i.e., CD20+, EBV-associated, IS still ongoing).

AVD, adriamycin, vinblastine, dacarbazine; Benda, Bendamustine; BV, brentuximab-vedotin; CAD, cyclophosphamide, doxorubicin, and dexamethasone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; DLBCL, diffuse large B-cell lymphoma; DLI, Donor lymphocyte infusion; GMALL07/2003, study protocol containing daunorubicin and doxorubicin; GMALL-B-NHL 2002, protocol containing R, Dexa, vincristine, MTX, ifosfamide, cytarabine, etoposide, cyclophosphamide, doxorubicin; HCC,

Hepatocellular carcinoma; IDA-FLAG, idarubicin, fludarabine, cytarabine, G-CSF; IS, immunosuppression; Mito-FLAG, mitoxantrone, fludarabine, cytarabine, G-CSF; monom., monomorphic; MTX, Methotrexate; PD, Progressive disease; Pola, Polatuzumab-Vedotin; PSC, Primary sclerosing cholangitis; R, Rituximab; RIS, Reduction of immunosuppression; RTx, Radiotherapy; thalidomide, doxorubicin, Dexa; VST, Virus-specific T cells. Values in bold means the summarized values.’

The correct footnote appears below. The publisher apologizes for this mistake.

^aSince/at diagnosis of PTLN, respectively. ^bWhere applicable (i.e., CD20+, EBV-associated, IS still ongoing).

AVD, adriamycin, vinblastine, dacarbazine; Benda, Bendamustine; BV, brentuximab-vedotin; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; DLI, Donor lymphocyte infusion; GMALL-B-NHL 2002, protocol containing R, Dexa, vincristine, MTX, ifosfamide, cytarabine, etoposide, cyclophosphamide, doxorubicin; IS, immunosuppression; Mito-FLAG, mitoxantrone, fludarabine, cytarabine, G-CSF; monom, monomorphic; MTX, Methotrexate; PD, Progressive disease; Pola, Polatuzumab-Vedotin; R, Rituximab; RIS, Reduction of immunosuppression; RTx, Radiotherapy; VST, Virus-specific T cells.’

Due to a production error, there was a mistake in Table 1 as published. ‘IDA-FLAG’ was incorrectly written as ‘DA-FLAG’, ‘Alcoholic cirrhosis’ was incorrectly written as ‘alcoholic cinhosis’, and ‘Multiple Myeloma’ was incorrectly written as ‘Myelom’. The corrected Table 1 appears below. The publisher apologizes for this mistake.

TABLE 1

Patient ID	Age ^a	Sex	Tx type	Indication for Tx	Previous anthracycline-containing treatments	Conditioning	Time from Tx (months/yr) ^a	Histology ^a	EBV+ (Lymphoma/Blood)	Ann Arbor stage ^a	ECOG ^a	IPI ^a
PTLD after HSCT:												
HSCT1	36	m	2nMMUD	sAML	1x 7 + 3, 1x IDA-FLAG	MA	2(0.2)	monom, DLBCL	pos/pos	n/a	3	n/a
HSCT2	65	m	MUD	AML	1x 7 + 3, 1x HAM	NMA	2(0.2)	n/a	na/pos	.	4	4
HSCT3	46	m	MUD	sAA	none	NMA	0(0)	n/a	na/pos	.	3	3
HSCT4	59	m	MUD	PCL	1x CAD	NMA	6(0.5)	n/a	na/pos	IV	3	3
HSCT5	61	m	MMUD	AML	2x 7 + 3, 1x HAM	MA	2(0.2)	n/a	na/pos	n/a	3	n/a
HSCT6	32	m	MUD	sAA	none	NMA	8(0.7)	monom, DLBCL	pos/pos	I	1	0
HSCT7	64	W	2 nd MUD	CNL	1x Mito-FLAG, 1x IDA- FLAG	NMA	4(0.3)	monom, DLBCL	pos/pos	IV	3	4
HSCT8	48	W	MUD	cALL	treatment within the GMALL 07/2003 trial	MA	2(0.2)	monom, MM	neg/pos	IV	3	3
HSCT9	64	m	AMMUD	sAML	2x 7 + 3	NMA	58(4.8)	monom Burkitt	neg/neg	IV	1	3
HSCT10	60	m	MUD	sAA	none	MA	1(0.1)	polymorphic	pos/pos	IV	2	3
HSCT11	61	m	MUD	sAA	none	MA	1(0.1)	n/a	na/pos	I	1	2
HSCT12	57	m	2 nd MUD	T-ALL&AML	1x 7 + 3	MA	2(0.2)	monom, DLBCL	pos/pos	IV	2	3
HSCT13	47	m	MUD	Metachromatic leukodystrophy	none	NMA	2(0.2)	monom, DLBCL	pos/pos	.	2	3
HSCT14	50	w	MUD	Multiple Myeloma	3x TAD, 1x CAD	NMA	81 (6.7)	cHL	pos/na	I	0	0
HSCT15	67	w	MRD	MDS EB2	none	NMA	3(0.3)	monom., T-LBL	neg/neg	IV	2	5
Median/%	59	73%	93% U	67% malignancies	60% anthracyclines		2(0.17)	80% monom.	87% assoc.	IV	2	3
PTLD after SOT:												
SOT1	53	W	Kidney	CKD, Fabry disease			133(11.1)	monom, DLBCL	neg/na	I	1	0

(Continued)

TABLE 1 Continued

Patient ID	Age ^a	Sex	Tx type	Indication for Tx	Previous anthracycline-containing treatments	Conditioning	Time from Tx (months/yr) ^a	Histology ^a	EBV+ (Lymphoma/Blood)	Ann Arbor stage ^a	ECOG ^a	IPI ^a
SOT2	31	m	Kidney	Monolateral renal agenesis			118(9.8)	monom, DLBCL	neg/neg	IV	3	3
SOT3	29	m	Liver	PSC, autoimmune hepatitis			70 (5.8)	monom, DLBCL	pos/neg	IV	1	3
SOT4	74	W	Liver	Autoimmune hepatitis			80 (6.7)	polymorphic	pos/pos	IV	3	4
SOT5	67	W	Kidney	CKD, chr. glomerulonephritis			233 (19.4)	monom, DLBCL	neg/na	IV	2	4
SOT6	57	m	Liver	Alcoholic cirrhosis			4 (0.3)	monom, PBL	pos/pos	I	2	1
SOT7	54	m	Liver	HCC, alcoholic cirrhosis			44 (3.7)	monom, DLBCL	neg/neg	IV	2	3
SOT8	67	m	Liver	Alcoholic cirrhosis			132 (11)	monom, DLBCL	neg/na	I	2	3
SOT9	45	m	Kidney & Pancreas	CKD, T1D			132 (11)	polymorphic	neg/neg	IV	2	4
SOT10	48	W	Liver	Alcoholic cirrhosis			5 (0.4)	polymorphic	pos/neg	IV	2	4
Median/%	54	60%/m		10% malignancies			99 (8.3)	70% monom.	40% assoc.	IV	2	3